Summary:
A 12 week treatment, multi center, randomized, double blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of Qva149 (indacaterol maleate/glycopyrronium bromide) in COPD patients with moderate to severe airflow limitation.
Qualified Participants Must:
• Be diagnosed with COPD
•
Be at least 40 years of age
•
Be a current or ex smoker
Qualified Participants May Receive:
$860.00 for 12 completed study visits, all clinic visits, chest x-ray, lab work, TB test and study medication at no charge.